Molecular Target Profile Analysis Of Luteolin And Lupeol For Colon Cancer Therapy | 38955
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

2nd International Conference on Biotechnology and Healthcare

Auckland, New Zealand
Google scholar citation report
Citations : 1514

Journal of Biotechnology & Biomaterials received 1514 citations as per google scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Molecular target profile analysis of luteolin and lupeol for colon cancer therapy

6th World Congress on Biotechnology

Rashmi K Ambasta

Delhi Technological University, India

ScientificTracks Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X.C1.043

Colon cancer is one of the main causes of mortality worldwide and several anti-cancer drugs are known for ages but still new therapeutical research is ongoing to target the anti-cancer drug at tumour specific site with lesser side effect. We set out to investigate comparative role of biomolecules like luteolin, and lupeol in cancer therapy via its anti-angiogenic mechanism. We have compared the role of anti-angiogenic drug via chick chorioallantoic membrane assay, colon cancer cell line proliferation ability and cell migration assay. Upon comparing the anti-angiogenic ability luteolin followed by lupeol has been found to be the best in inhibiting angiogenesis, cell proliferation ability and cell migration ability. Colon tumour has been analyzed for FISH and immunohistochemistry. Expression of VEGF, EGFR, FGFR has been analyzed. VEGF and FGFR are overexpressed in colon tumour compared to EGFR. Hence effect of biomolecule luteolin is analyzed in colon cancer cell line via western blotting for these signaling pathway dissections. Therefore, it can be concluded that luteolin is the best screened anti-cancerous drug which targets several downstream targets of VEGF and FGF pathway.

Rashmi KAmbasta is working as a Principal Investigator and SERB-DST Scientist at Department of Biotechnology, Delhi Technological University. She has finished her Master’s degree from the Department of Zoology, Banaras Hindu University. She has qualified national level exam for CSIR-JRF, ICMR-JRF, and ASRB-LS. She has joined J W Goethe University for her PhD in Frankfurt Germany. She has finished her PhD in 2004 and joined Boston, MA, USA for her two Postdoctoral training sponsored by NIH. She joined the faculty position at VIT, Vellore, India as an Assistant Professor and was promoted to Associate Professor. She was awarded with DST-Young Scientist Award under fasttrack scheme. Her research interest is in the field of Cancer Drug Targeting. She has published six book chapters, several conference abstracts and more than 25 articles (cumulative IF=60; cumulative citation 663; h index=8) in well reputed journals. She has been an invited speaker at Universities like BHU, Varanasi, IIT- Delhi, AIIMS-Delhi, and JMI-Delhi. She is a life member of SBTI, SNCI and member of IACR.

Email: [email protected]